NEOG Fundamental Analysis - NEOGEN CORP

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to NEOG. NEOG was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While NEOG seems to be doing ok healthwise, there are quite some concerns on its profitability. NEOG has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

NEOG had positive earnings in the past year.

In the past year NEOG had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: NEOG reported negative net income in multiple years.

Each year in the past 5 years NEOG had a positive operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -31.71%, NEOG is in line with its industry, outperforming 42.93% of the companies in the same industry.

The Return On Equity of NEOG (-52.72%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-31.71%
ROE	-52.72%
ROIC	N/A

ROA(3y)-10.81%

ROA(5y)-4.19%

ROE(3y)-17.92%

ROE(5y)-8.21%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NEOG's Gross Margin of 47.10% is in line compared to the rest of the industry. NEOG outperforms 40.84% of its industry peers.

In the last couple of years the Gross Margin of NEOG has remained more or less at the same level.

NEOG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	47.1%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.72%

GM growth 5Y0.07%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, NEOG has about the same amount of shares outstanding.

The number of shares outstanding for NEOG has been increased compared to 5 years ago.

The debt/assets ratio for NEOG is higher compared to a year ago.

2.2 Solvency

NEOG has an Altman-Z score of 0.71. This is a bad value and indicates that NEOG is not financially healthy and even has some risk of bankruptcy.

NEOG's Altman-Z score of 0.71 is in line compared to the rest of the industry. NEOG outperforms 49.21% of its industry peers.

NEOG has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.42, NEOG is in line with its industry, outperforming 45.03% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.42
Debt/FCF	N/A
Altman-Z	0.71

ROIC/WACCN/A

WACC7.64%

2.3 Liquidity

A Current Ratio of 3.32 indicates that NEOG has no problem at all paying its short term obligations.

NEOG has a better Current ratio (3.32) than 62.83% of its industry peers.

NEOG has a Quick Ratio of 2.22. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 2.22, NEOG is in line with its industry, outperforming 57.07% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.32
Quick Ratio	2.22

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NEOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.

Measured over the past years, NEOG shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -10.20% on average per year.

Looking at the last year, NEOG shows a decrease in Revenue. The Revenue has decreased by -3.20% in the last year.

Measured over the past years, NEOG shows a quite strong growth in Revenue. The Revenue has been growing by 16.43% on average per year.

EPS 1Y (TTM)-25%

EPS 3Y-9.82%

EPS 5Y-10.2%

EPS Q2Q%-50%

Revenue 1Y (TTM)-3.2%

Revenue growth 3Y19.28%

Revenue growth 5Y16.43%

Sales Q2Q%-4.79%

3.2 Future

NEOG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.40% yearly.

NEOG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.60% yearly.

EPS Next Y-24.27%

EPS Next 2Y3.26%

EPS Next 3Y-1.41%

EPS Next 5Y0.4%

Revenue Next Year-7.92%

Revenue Next 2Y-3.15%

Revenue Next 3Y-1.21%

Revenue Next 5Y0.6%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 17.30 indicates a rather expensive valuation of NEOG.

Based on the Price/Earnings ratio, NEOG is valued cheaper than 81.68% of the companies in the same industry.

NEOG's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.76.

With a Price/Forward Earnings ratio of 22.85, NEOG is valued on the expensive side.

Compared to the rest of the industry, the Price/Forward Earnings ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 76.96% of the companies listed in the same industry.

When comparing the Price/Forward Earnings ratio of NEOG to the average of the S&P500 Index (23.18), we can say NEOG is valued inline with the index average.

		Industry Rank	Sector Rank
PE	17.3
Fwd PE	22.85

4.2 Price Multiples

NEOG's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NEOG is cheaper than 78.01% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	15.96

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y3.26%

EPS Next 3Y-1.41%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NEOG does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEOGEN CORP

NASDAQ:NEOG (9/30/2025, 8:24:33 PM)

After market: 5.8 +0.09 (+1.58%)

5.71

+0.12 (+2.15%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)07-29 2025-07-29/bmo

Earnings (Next)10-09 2025-10-09

Inst Owners112.45%

Inst Owner Change-5%

Ins Owners0.42%

Ins Owner Change84.69%

Market Cap1.24B

Analysts78

Price Target6.63 (16.11%)

Short Float %9.97%

Short Ratio3.42

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-22.76%

Min EPS beat(2)-34.64%

Max EPS beat(2)-10.87%

EPS beat(4)1

Avg EPS beat(4)-13.3%

Min EPS beat(4)-34.64%

Max EPS beat(4)11.56%

EPS beat(8)1

Avg EPS beat(8)-15.08%

EPS beat(12)3

Avg EPS beat(12)39.16%

EPS beat(16)4

Avg EPS beat(16)23.61%

Revenue beat(2)0

Avg Revenue beat(2)-2.03%

Min Revenue beat(2)-3.66%

Max Revenue beat(2)-0.4%

Revenue beat(4)0

Avg Revenue beat(4)-1.34%

Min Revenue beat(4)-3.66%

Max Revenue beat(4)-0.19%

Revenue beat(8)1

Avg Revenue beat(8)-1.4%

Revenue beat(12)2

Avg Revenue beat(12)-1.25%

Revenue beat(16)3

Avg Revenue beat(16)-1%

PT rev (1m)0%

PT rev (3m)-23.53%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-7.69%

EPS NY rev (1m)0%

EPS NY rev (3m)20.49%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-6.22%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-8.36%

Valuation

		Industry Rank	Sector Rank
PE	17.3
Fwd PE	22.85
P/S	1.39
P/FCF	N/A
P/OCF	21.29
P/B	0.6
P/tB	N/A
EV/EBITDA	15.96

EPS(TTM)0.33

EY5.78%

EPS(NY)0.25

Fwd EY4.38%

FCF(TTM)-0.21

FCFYN/A

OCF(TTM)0.27

OCFY4.7%

SpS4.12

BVpS9.54

TBVpS-1.86

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-31.71%
ROE	-52.72%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	47.1%
FCFM	N/A

ROA(3y)-10.81%

ROA(5y)-4.19%

ROE(3y)-17.92%

ROE(5y)-8.21%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.72%

GM growth 5Y0.07%

F-Score3

Asset Turnover0.26

Health

		Industry Rank	Sector Rank
Debt/Equity	0.42
Debt/FCF	N/A
Debt/EBITDA	7.06
Cap/Depr	83.23%
Cap/Sales	11.69%
Interest Coverage	N/A
Cash Conversion	46.97%
Profit Quality	N/A
Current Ratio	3.32
Quick Ratio	2.22
Altman-Z	0.71

F-Score3

WACC7.64%

ROIC/WACCN/A

Cap/Depr(3y)83.18%

Cap/Depr(5y)95.92%

Cap/Sales(3y)10.58%

Cap/Sales(5y)8.42%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-25%

EPS 3Y-9.82%

EPS 5Y-10.2%

EPS Q2Q%-50%

EPS Next Y-24.27%

EPS Next 2Y3.26%

EPS Next 3Y-1.41%

EPS Next 5Y0.4%

Revenue 1Y (TTM)-3.2%

Revenue growth 3Y19.28%

Revenue growth 5Y16.43%

Sales Q2Q%-4.79%

Revenue Next Year-7.92%

Revenue Next 2Y-3.15%

Revenue Next 3Y-1.21%

Revenue Next 5Y0.6%

EBIT growth 1Y-102.86%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year136.85%

EBIT Next 3Y34.41%

EBIT Next 5Y19.96%

FCF growth 1Y39.14%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y65.17%

OCF growth 3Y-5.05%

OCF growth 5Y-7.47%

NEOGEN CORP (NEOG) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens